Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well linsitinib works in treating patients with asymptomatic
or mild symptomatic metastatic prostate cancer. Linsitinib may stop the growth of tumor cells
by blocking some of the enzymes needed for cell growth.